Abstract:Objective: To investigate novel coronavirus pneumonia T lymphocyte subsets and its clinical significance. Methods: 88 novel coronavirus pneumonia patients were selected as the observation group, and 30 healthy people as control group. There was no significant difference in gender and age between the two groups (P > 0.05).The T lymphocyte subsets were detected by flow cytometry, and their clinical significance was analyzed. Results: The absolute numbers of CD4 + and CD8 + in peripheral blood of 88 patients were 335.000 (196.000,499.000) and 223.000 (118.000,324.000) respectively, which were significantly lower than those of healthy control group (1027.933 ± 235.014 and 727.033 ± 210.633), the difference between groups was statistically significant (P<0.01) There was no significant difference in the percentage of CD4 +, CD8 + and the ratio of CD4 + / CD8 + between the two groups (P>0.05). There was significant difference in the absolute number of CD4 + and CD8 + T cells among the three groups (P<0.01). ROC analysis showed that CD4 + and CD8 + had clinical significance in judging disease aggravation, and the best critical values were 362 / UL and 222 / UL respectively. Conclusion: The absolute numbers of CD4 + and CD8 + T in the peripheral blood of COVID-2019 are reduced to some extent, which may help to predict the development and prognosis of the disease and guide the clinical treatment.
[1] 新型冠状病毒肺炎诊疗方案(试行第七版)[J].心肺血管病杂志,2020,39(2):103~107. [2] Wang W J, He J X, Lie p y. The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis[EB/OL]. [3] Xu Z, Shi L, Wang Yet al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. The Lancet. Respiratory medicine,2020,8(4): 420~422 [4] Diao B, Wang C, Tan Yet al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)[J]. Frontiers in immunology,2020,11: 827 [5] Thevarajan I, Nguyen T H O, Koutsakos M, et al. Breadth of concomitant immune responses underpinning viral clearance and patient recovery in a non-severe case of COVID-19[J]. [6] Wan SX, Yi QJ, Fan SB, et al.Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)[EB/OL].https://www.medrxiv.org/content/10.1101/2020.02.10.20021832v1. [7] Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic[J]. Asian Pacific journal of allergy and immunology,2020,38(1): 1~9 [8] Cai, X. An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis[EB/OL].https://doi.org/10.31219/osf.io/hw34x.